[Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the emerging role of the Cardiomyopathy Team].

L’alcolizzazione del setto interventricolare nella cardiomiopatia ipertrofica ostruttiva: il ruolo emergente del Cardiomyopathy Team.

Journal

Giornale italiano di cardiologia (2006)
ISSN: 1972-6481
Titre abrégé: G Ital Cardiol (Rome)
Pays: Italy
ID NLM: 101263411

Informations de publication

Date de publication:
03 2021
Historique:
entrez: 13 4 2021
pubmed: 14 4 2021
medline: 16 10 2021
Statut: ppublish

Résumé

Alcohol septal ablation is a minimally invasive, safe, and effective procedure for the treatment of left ventricular outflow tract (LVOT) obstruction in patients with hypertrophic obstructive cardiomyopathy (HOCM) who remain symptomatic despite maximal medical therapy. Originally performed by Ulrich Sigwart in 1994, the procedure causes a iatrogenic infarction - through the injection of absolute alcohol - of the basal portion of the interventricular septum and aims at reducing LVOT obstruction in order to improve patient's hemodynamics and symptoms. Numerous studies have demonstrated the effectiveness and safety of the procedure, making it a valid alternative to surgical myectomy. The success of alcohol septal ablation depends upon the selection of the patient and the experience of both the operators and the center where the procedure is performed. In this review, we summarize current evidence on alcohol septal ablation, describe its procedural aspects and propose a multidisciplinary approach that involves a team of clinical cardiologists, interventionists, and cardiac surgeons, the Cardiomyopathy Team, with high experience in the clinical management of these patients.

Identifiants

pubmed: 33847320
doi: 10.1714/3578.35631
doi:

Substances chimiques

Ethanol 3K9958V90M

Types de publication

Journal Article Review

Langues

ita

Sous-ensembles de citation

IM

Pagination

25S-31S

Auteurs

Felice Gragnano (F)

Cattedra di Cardiologia, Università della Campania "Luigi Vanvitelli", U.O.C. Cardiologia-UTIC, AORN Sant'Anna e San Sebastiano, Caserta.

Vincenzo Pasceri (V)

U.O. Cardiologia, Dipartimento Cardiovascolare, Ospedale San Filippo Neri, Roma.

Giuseppe Limongelli (G)

U.O. Cardiologia Pediatrica e U.O. Riabilitazione e Scompenso Cardiaco, Ospedale Monaldi, A.O. dei Colli, Dipartimento di Scienze Cardio-Toraciche e Respiratorie, Seconda Università degli Studi, Napoli.

Gaetano Tanzilli (G)

U.O. Cardiologia e Angiologia, Dipartimento di Scienze Cardiovascolari, Sapienza Università di Roma, Roma.

Paolo Calabrò (P)

Cattedra di Cardiologia, Università della Campania "Luigi Vanvitelli", U.O.C. Cardiologia-UTIC, AORN Sant'Anna e San Sebastiano, Caserta.

Francesco Pelliccia (F)

U.O. Cardiologia e Angiologia, Dipartimento di Scienze Cardiovascolari, Sapienza Università di Roma, Roma.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH